Exhibit B

Buchanan Ingersoll & Rooney LLP
Attorneys & Government Relations Professionals

12230 El Camino Real, Suite 300
San Diego, CA 92130
Telephone: +1.858.509.7337
Facsimile: +1.858.509.7353
www.buchananingersoll.com

FACSIMILE COVER

Date: August 16, 2006

TO:	**Dr. Weber**		
Fax Number:	**(571) 273-0925**	Company:	USPTO
Telephone:		Your Reference:	10/815,562
FROM:	**Joseph R. Baker, Jr.**		
Telephone:	(858) 509-7373	Our Reference:	1034123-000096
Sent By:	Kim A. Cabello	Number of Pages Including Cover:	3

Message

DRAFT - NOT FOR ENTRY IN TO FILE

Proposed Amendments to the Claims.

 fornia

DRAFT - NOT FOR ENTRY IN TO FILE
Attorney's Docket No. 1034123-000096

In re Patent Application of	Group Art Unit: 1653
Mohamed Zaiou *et al.*	Examiner: MITRA, RITA
Application No.: 10/815,562	Confirmation No.: 5767
Filed: March 31, 2004	
For: THERAPY FOR MICROBIAL INFECTIONS	

VIA FACSIMILE (1-571-273-0925)

Dear Dr. Weber:

It was a pleasure speaking with you on the afternoon of August 14th. Per our recent telephonic interview, please find some suggested claim language. Claim 22 has been amended as a Markush, however, we would be happy to set forth separate claims as needed.

Warmest regards.

Respectfully yours,

Joseph Baker (Reg. No. 40,900)

PROPOSED AMENDMENTS TO THE CLAIMS:

22. (Currently Amended) A method for inhibiting the growth of a bacterium or yeast comprising contacting the bacterium or yeast with an inhibiting effective amount of a cathelin-like ~~precursor~~ polypeptide selected from the group consisting of:

a) a polypeptide consisting of amino acid residues 31 to 131 of SEQ ID NO:2 and having 1-10 conservative amino acid substitutions;

b) a polypeptide consisting of amino acid residues 31 to 131 of SEQ ID NO:2 and having 1-10 additional amino acid residues at the amino-terminus and/or carboxy-terminus, wherein the additional amino acid residues are heterologous to residues 1-30 of SEQ ID NO:2 and/or residues 132-170 of SEQ ID NO:2; and

c) a polypeptide consisting of amino acid residues X_2 to X_3, wherein X_2 is an amino acid residue between and inclusive of residues 29-31 of SEQ

ID NO:2, and wherein X_3 is an amino acid residue between and inclusive of residues 128-131 of SEQ ID NO:2,

~~as cathelin-like peptide or variant consisting essentially of an amino acid sequence as set forth in SEQ ID NO:2 from about amino acid 31 to 131,~~ wherein the ~~cathelin-like peptide or variant is a~~ polypeptide comprises cysteine proteinase inhibitor activity or ~~and/or exhibits~~ antibacterial activity, or a combination thereof.

23. (Currently Amended) The method of claim 22, wherein ~~the cathelin-like peptide variant has 1-10 conservative amino acid substitutions between~~ amino acid residues 31-131 ~~31 and 131~~ of SEQ ID NO:2 include 1-5 conservative amino acid substitutions.

24. (Cancelled)

25. (New) A method for inhibiting the growth of a bacterium or yeast comprising contacting the bacterium or yeast with an inhibiting effective amount of a polypeptide selected from the group consisting of:

a) a polypeptide comprising amino acid residues 31 to 131 of SEQ ID NO:2 including 1-10 conservative amino acid substitutions, and excluding:
   i) residues 1-30 of SEQ ID NO:2 contiguous with the amino terminus of residues 31-131 of SEQ ID NO:2; and
   ii) residues 132-170 of SEQ ID NO:2 contiguous with the carboxy-terminus of residues 31-131 of SEQ ID NO:2; and

b) a polypeptide comprising amino acid residues 31 to 131 of SEQ ID NO:2, and excluding:
   i) residues 1-30 of SEQ ID NO:2 contiguous with the amino terminus of residues 31-131 of SEQ ID NO:2; and
   ii) residues 132-170 of SEQ ID NO:2 contiguous with the carboxy-terminus of residues 31-131 of SEQ ID NO:2;

wherein residues 31-131 of SEQ ID NO:2 comprise cysteine proteinase inhibitor activity or antibacterial activity, or a combination thereof.

Exhibit C

Cancel claims non-elected claims 1, 11, 12 and 14-21, without prejudice or disclaimer.

22. (Currently Amended) A method for inhibiting the growth of a bacterium or yeast comprising contacting the bacterium or yeast with an inhibiting effective amount of a polypeptide selected from the group consisting of:

a) a polypeptide consisting of amino acid residues 31 to 131 of SEQ IQ NO:2 and having 1-10 conservative amino acid substitutions:

b) a polypeptide comprising amino acid residues 31 to 131 of SEQ ID NO:2 and having 1-10 additional amino acid residues at the amino-terminus and/or carboxy-terminus wherein the additional amino acid residues are heterologous to residues 1-30 of SEQ ID NO:2 and/or residues 132-170 of SEQ ID NO:2; and

c) a polypeptide consisting of amino acid residues X_2 to X_3, wherein X_2 is an amino acid residue selected from the group consisting of residues 29, 30 and 31 of SEQ ID N0:2, and wherein X_3 is an amino acid residue selected from the group consisting of residues 128, 129, 130 and 131 of SEQ ID N0:2,

~~as cathelin-like peptide or variant consisting essentially of an amino acid sequence as set forth in SEQ ID NO:2 from about amino acid 31-131,~~

wherein the ~~cathelin-like peptide or variant is a~~ polypeptide comprises cysteine proteinase inhibitor activity or ~~and/or~~ exhibits antibacterial activity, or a combination thereof.

23. (Currently Amended) The method of claim 22, wherein ~~the cathelin-like peptide variant has 1-10 conservative amino acid substitutions between~~ amino acid residues 31-131 ~~31 and 131~~ of SEQ ID N0:2 include 1-5 conservative amino acid substitutions.

24. (Cancelled)

25. (New) A method for inhibiting the growth of a bacterium or yeast comprising

contacting the bacterium or yeast with an inhibiting effective amount of a

polypeptide selected from the group consisting of:

a) a polypeptide comprising amino acid residues 31 to 131 of SEQ ID

N0:2 including 1-10 conservative amino acid substitutions, and

excluding:

i) residues 1-30 of SEQ ID N0:2 contiguous with the amino

terminus of residues 31-131 of SEQ ID N0:2; and

ii) residues 132-170 of SEQ ID N0:2 contiguous with the carboxy-

terminus of residues 31-131 of SEQ ID N0:2; and

b) a polypeptide comprising amino acid residues 31 to 131 of SEQ ID

N0:2, and excluding:

i) residues 1-30 of SEQ ID N0:2 contiguous with the amino

terminus of residues 31-131 of SEQ ID N0:2; and

ii) residues 132-170 of SE0 ID N0:2 contiguous with the carboxy-

terminus of residues 31-131 of SEQ ID N0:2;

wherein residues 31-131 of SEQ ID N0:2 comprise cysteine proteinase

inhibitor activity or antibacterial activity, or a combination thereof.